SCHEMBL2986196

SCHEMBL2986196

CCCC#Cc1ccnc2c1c(C(C)=O)cn2S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR6 P50406 3/20 0.36
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 2/20 0.34
PLK1 P53350 1/20 0.34
MEN1 O00255 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
PKM P14618 2/20 0.33
TNFSF11 O14788 1/20 0.33
TNF P01375 3/20 0.33
GAA P10253 2/20 0.31
PIK3C3 Q8NEB9 1/20 0.31
AKR1C3 P42330 1/20 0.31
AKR1C1 Q04828 1/20 0.31
MET P08581 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998178 0.85 LMNA (0.46) LMNASMN1; SMN2HTR6CYP2C19KMT2A
SCHEMBL2998009 0.85 SMN1; SMN2 (0.36) LMNASMN1; SMN2HTR6CYP2C19KMT2A
SCHEMBL2998005 0.80 CA9 (0.33) HTR6CYP2C19PTGDR2TNFSF11
SCHEMBL2994911 0.78 LMNA (0.46) LMNASMN1; SMN2HTR6CYP2C19KMT2A
SCHEMBL2986139 0.78 LMNA (0.47) LMNASMN1; SMN2HTR6CYP2C19KMT2A
SCHEMBL2237471 0.77 LMNA (0.51) LMNASMN1; SMN2HTR6CYP2C19KMT2A
SCHEMBL2995288 0.76 LMNA (0.50) LMNASMN1; SMN2HTR6CYP2C19KMT2A
SCHEMBL2999849 0.76 LMNA (0.49) LMNASMN1; SMN2HTR6CYP2C19KMT2A
SCHEMBL2995312 0.74 SMN1; SMN2 (0.46) LMNASMN1; SMN2HTR6CYP2C19KMT2A
SCHEMBL2993407 0.74 LMNA (0.47) LMNASMN1; SMN2HTR6CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125803-B1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NAT RECH SCIENT (FR) 2013-04-10 EP disclosed
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF BAD, PPOX, CASP3 LMNA 4217/4885SMN1; SMN2 954/4885HTR6 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.